![](/img/cover-not-exists.png)
An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine
Robert T Schoen, Terry Deshefy-Longhi, Christian Van-Hoecke, Charles Buscarino, Erol FikrigVolume:
25
Year:
2003
Language:
english
DOI:
10.1016/s0149-2918(03)90027-0
File:
PDF, 816 KB
english, 2003